Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 25, Issue 3, Pages 552-563
Publisher
Oxford University Press (OUP)
Online
2013-11-22
DOI
10.1093/annonc/mdt419
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract 5195: Kidney injury molecule-1: a novel therapeutic target in renal cell carcinoma.
- (2014) Venkata Sabbisetti et al. CANCER RESEARCH
- Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
- (2013) Joseph M. Gozgit et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma
- (2013) K. Zhang et al. CANCER RESEARCH
- Identification of recurrentFGFR3fusion genes in lung cancer through kinome-centred RNA sequencing
- (2013) Ian J Majewski et al. JOURNAL OF PATHOLOGY
- Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
- (2013) Hideki Terai et al. MOLECULAR CANCER RESEARCH
- Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
- (2013) G. E. Konecny et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
- (2013) David T W Jones et al. NATURE GENETICS
- Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
- (2013) NATURE GENETICS
- FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells
- (2013) Sungeun Kim et al. PLoS One
- Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer
- (2013) T. C. Harding et al. Science Translational Medicine
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
- (2013) Maria Vittoria Dieci et al. Cancer Discovery
- A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
- (2013) K E Ware et al. Oncogenesis
- FGFR2 gene amplification and clinicopathological features in gastric cancer
- (2012) K Matsumoto et al. BRITISH JOURNAL OF CANCER
- Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
- (2012) C Oliveras-Ferraros et al. BRITISH JOURNAL OF CANCER
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
- (2012) P. R. Gavine et al. CANCER RESEARCH
- Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression
- (2012) S. Feng et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
- (2012) A. N. Brooks et al. CLINICAL CANCER RESEARCH
- Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
- (2012) J. Zhang et al. CLINICAL CANCER RESEARCH
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Oncogenic FGFR3 gene fusions in bladder cancer
- (2012) Sarah V. Williams et al. HUMAN MOLECULAR GENETICS
- Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
- (2012) Vipin Yadav et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer
- (2012) Hye Ryun Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma
- (2012) Eleonora Brunello et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- FGFR1 Amplification in Squamous Cell Carcinoma of The Lung
- (2012) Rebecca S. Heist et al. Journal of Thoracic Oncology
- Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
- (2012) Hans-Ulrich Schildhaus et al. MODERN PATHOLOGY
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
- (2012) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- Molecular prescreening to select patient population in early clinical trials
- (2012) Jordi Rodón et al. Nature Reviews Clinical Oncology
- FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
- (2012) Sara A. Byron et al. PLoS One
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
- (2012) V. Guagnano et al. Cancer Discovery
- Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth
- (2012) Fred Harbinski et al. Cancer Discovery
- Fibroblast growth factors and their receptors in cancer
- (2011) Jørgen Wesche et al. BIOCHEMICAL JOURNAL
- Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
- (2011) Eric T. Sawey et al. CANCER CELL
- FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo
- (2011) Rachel Sharpe et al. CLINICAL CANCER RESEARCH
- Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
- (2011) C. Lieu et al. CLINICAL CANCER RESEARCH
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
- (2011) K. B. Kim et al. CLINICAL CANCER RESEARCH
- Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
- (2011) Elizabeth Allen et al. CLINICAL CANCER RESEARCH
- Fibroblast Growth Factor Signaling in Non–Small-Cell Lung Cancer
- (2011) Thomas J. Semrad et al. Clinical Lung Cancer
- Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
- (2011) Hikmat A Al-Ahmadie et al. JOURNAL OF PATHOLOGY
- Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4
- (2011) Daniela Bumbaca et al. mAbs
- A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
- (2011) G. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs
- (2011) R. Dienstmann et al. ONCOLOGIST
- Targeting mutant fibroblast growth factor receptors in cancer
- (2011) Heidi Greulich et al. TRENDS IN MOLECULAR MEDICINE
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
- (2010) F R Lamont et al. BRITISH JOURNAL OF CANCER
- GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling
- (2010) A. Bai et al. CANCER RESEARCH
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts
- (2010) W.-m. Zhao et al. CLINICAL CANCER RESEARCH
- Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma
- (2010) Nadège Gruel et al. EUROPEAN JOURNAL OF CANCER
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
- (2010) Kathryn E. Ware et al. PLoS One
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate
- (2009) Christine Y. Shiang et al. BREAST CANCER RESEARCH AND TREATMENT
- The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth In vitro and In vivo
- (2009) O. E. Pardo et al. CANCER RESEARCH
- Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
- (2009) Jing Qing et al. JOURNAL OF CLINICAL INVESTIGATION
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- (2009) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- 1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regulation of p27/Kip1 and G1/G0 Arrest
- (2009) M. Miyake et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
- (2009) Michael G. Gartside et al. MOLECULAR CANCER RESEARCH
- Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis
- (2009) S S Kwek et al. ONCOGENE
- De-regulated FGF receptors as therapeutic targets in cancer
- (2009) Victoria Knights et al. PHARMACOLOGY & THERAPEUTICS
- Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
- (2009) Yongping Crawford et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
- (2008) K. Kunii et al. CANCER RESEARCH
- High-resolution genomic and expression analyses of copy number alterations in breast tumors
- (2008) Peter M. Haverty et al. GENES CHROMOSOMES & CANCER
- Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
- (2008) Alvaro Moreno-Aspitia et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions
- (2008) Kumiko Maruyama-Takahashi et al. PROSTATE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now